Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.46 USD
0.00 (-0.04%)
Updated May 31, 2024 03:56 PM ET
After-Market: $0.45 -0.01 (-1.77%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Redhill Biopharma Ltd. [RDHL]
Reports for Purchase
Showing records 101 - 120 ( 228 total )
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Commercial stage, GI-focused R-D pharma
Provider: EDISON INVESTMENT RESEARCH LIMITED
Analyst: PECIULIS J
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Continued GI product growth, CD PhIII data in 3M
Provider: EDISON INVESTMENT RESEARCH LIMITED
Analyst: PECIULIS J
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Two Upcoming Phase 3 Readouts; Yeliva Could Provide Upside; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
1Q18 Recap - RHB-104 (Crohn''s) Readout Targeted by August
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
A Growing Presence in GI Specialty Market; Phase 3 Results in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
A Strong Start for Donnatal and EnteraGam; Clinical Updates in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Rizaport NDA Resubmitted; On Track for U.S. Approval in 1H18
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Bekinda Could Become the New Standard of Care in IBS-D; New $36 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
IBS-D Trial Positive Despite Muted Share Price Reaction
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Reducing Size of Crohn''s Trial Saves Time and Money
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.